FRA
VKTX icon

Front Row Advisors’s Viking Therapeutics VKTX Stock Holding History

Front Row Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507 Buy
15
+3
+25% +$97 ﹤0.01% 543
2026
Q1 		$390 Buy
+12
New +$386 ﹤0.01% 538

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Front Row Advisors's VKTX Position: Q2 2026 in Review

Front Row Advisors increased its Viking Therapeutics (VKTX) stake by 25% in Q2 2026, buying an estimated $97 and bringing the position to 15 shares worth $507. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Front Row Advisors first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Front Row Advisors held 15 shares of Viking Therapeutics worth $507 as of Q2 2026.
  • Front Row Advisors bought 3 Viking Therapeutics shares in Q2 2026, an estimated $97.
  • Viking Therapeutics made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #543 holding.
  • Front Row Advisors first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.